Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for Early Dupuytren's Disease
NCT03180957Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Mar 2016
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of adalimumab in Dupuytren's disease, sponsored by University of Oxford. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
Dupuytren's disease
Beyond the preview
Go deeper on NCT03180957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03180957.